Biopharmaceutical company Suven Life Sciences, which is looking at raising about Rs 90 crore, is participating at the 29th JP Morgan Healthcare Conference being held at San Francisco, US, from January 10 to 13.
The company will explain business strategy, fund raising and partnering activities for its SUVN-502, which is ready for Phase IIa clinical studies. This is useful in dealing with Alzheimer’s and Schizophrenia, according to its chief executive officer Venkat Jasti.
The market potential of unmet medical needs in the central nervous system disorders segment is estimated at $20 billion. JP Morgan Healthcare Conference brings investment professionals and innovation companies on a common platform, a company release said here on Tuesday.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app